Research graph
References from Combination of Empagliflozin and Resveratrol Mitigates Hepatic Steatosis via Attenuation of Inflammation and Promotion of Adipose Tissue Browning in High‐Fat Diet‐Fed C57BL / 6J Mice. Local targets link to admitted publications; unresolved targets remain external evidence.
The Combination of Metformin With Morin Alleviates Hepatic Steatosis via Modulating Hepatic Lipid Metabolism, Hepatic Inflammation, Brown Adipose Tissue Thermogenesis, and White Adipose Tissue Browning in High‐Fat Diet‐Fed Mice
10.1016/j.lfs.2023.121706 · 2023 · External reference
Hepatic Insulin Resistance, Metabolic Syndrome and Cardiovascular Disease
10.1016/j.clinbiochem.2009.05.018 · 2009 · External reference
A Review of the Therapeutic Effects of Polyphenols on Non‐Alcoholic Fatty Liver Disease: Focus on Oxidative Stress
2024 · External reference
Molecular and Cellular Mechanisms Linking Inflammation to Insulin Resistance and β‐Cell Dysfunction
10.1016/j.trsl.2015.08.011 · 2016 · External reference
Adipokines as a Link Between Adipose Tissue With Inflammation and Insulin Resistance in Cardiometabolic Diseases
2023 · External reference
Recent Advances in Nanodelivery Systems for Polyphenols in Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): An Update
2025 · External reference
Molecular and Cellular Mechanisms Linking Inflammation to Insulin Resistance and Beta‐Cell Dysfunction
10.1016/j.trsl.2015.08.011 · 2016 · External reference
Browning of Adipocytes: A Potential Therapeutic Approach to Obesity
10.3390/nu15092229 · 2023 · External reference
Combination Therapy of Metformin and p‐Coumaric Acid Mitigates Metabolic Dysfunction Associated With Obesity and Nonalcoholic Fatty Liver Disease in High‐Fat Diet Obese C57BL/6 Mice
10.1016/j.jnutbio.2023.109369 · 2023 · External reference
SGLT‐2 Inhibitors in NAFLD: Expanding Their Role Beyond Diabetes and Cardioprotection
10.3390/ijms23063107 · 2022 · External reference
Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications Beyond Glycemic Control
10.3390/ijms24076039 · 2023 · External reference
Empagliflozin Protects Mice Against Diet‐Induced Obesity, Insulin Resistance and Hepatic Steatosis
10.1007/s00125-022-05851-x · 2023 · External reference
In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and Before Onset of Hyperglycemia
10.3390/ijms222111513 · 2021 · External reference
Anti‐Inflammatory Potential of Empagliflozin
10.1007/s10787-021-00797-9 · 2021 · External reference
Empagliflozin Attenuates Non‐Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE (−/−) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
10.3390/ijms22020818 · 2021 · External reference
Empagliflozin Induces White Adipocyte Browning and Modulates Mitochondrial Dynamics in KK Cg‐Ay/J Mice and Mouse Adipocytes
10.3389/fphys.2021.745058 · 2021 · External reference
SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet‐Induced Obese Mice
10.1016/j.ebiom.2017.05.028 · 2017 · External reference
Resveratrol as a Potential Protective Compound Against Skeletal Muscle Insulin Resistance
10.1016/j.heliyon.2023.e21305 · 2023 · External reference
Resveratrol as a Potential Protective Compound Against Metabolic Inflammation
2023 · External reference
Resveratrol Alleviates Obesity‐Induced Skeletal Muscle Inflammation via Decreasing M1 Macrophage Polarization and Increasing the Regulatory T Cell Population
10.1038/s41598-020-60185-1 · 2020 · External reference
Effects of Resveratrol and Its Derivative Pterostilbene on Brown Adipose Tissue Thermogenic Activation and on White Adipose Tissue Browning Process
10.1007/s13105-020-00735-3 · 2020 · External reference
Resveratrol Reduces High Glucose‐Induced de‐Novo Lipogenesis Through mTOR Mediated Induction of Autophagy in HepG2 Cells
2023 · External reference
Involvement of 5′ AMP‐Activated Protein Kinase (AMPK) in the Effects of Resveratrol on Liver Steatosis
10.3390/ijms19113473 · 2018 · External reference
Empagliflozin Reverses Obesity and Insulin Resistance Through Fat Browning and Alternative Macrophage Activation in Mice Fed a High‐Fat Diet
10.1136/bmjdrc-2019-000783 · 2019 · External reference
Resveratrol Alleviates Non‐Alcoholic Fatty Liver Disease Through Epigenetic Modification of the Nrf2 Signaling Pathway
10.1016/j.biocel.2019.105667 · 2020 · External reference
Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease
10.1002/hep.20701 · 2005 · External reference
10.1007/978-1-0716-3167-6_12
10.1007/978-1-0716-3167-6_12 · 2023 · External reference
Genetic and Diet‐Induced Animal Models for Non‐Alcoholic Fatty Liver Disease (NAFLD) Research
10.3390/ijms232415791 · 2022 · External reference
Mouse Models of Nonalcoholic Fatty Liver Disease (NAFLD): Pathomechanisms and Pharmacotherapies
10.7150/ijbs.65044 · 2022 · External reference
Resveratrol Improves Liver Steatosis and Insulin Resistance in Non‐Alcoholic Fatty Liver Disease in Association With the Gut Microbiota
10.3389/fmicb.2021.611323 · 2021 · External reference
Resveratrol Exerts Anti‐Obesity Effects via Mechanisms Involving Down‐Regulation of Adipogenic and Inflammatory Processes in Mice
10.1016/j.bcp.2011.03.012 · 2011 · External reference
Resveratrol Attenuates Dapagliflozin‐Induced Renal Gluconeogenesis via Activating the PI3K/Akt Pathway and Suppressing the FoxO1 Pathway in Type 2 Diabetes
10.1039/d0fo02387f · 2021 · External reference
Systemic Impacts of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH) on Heart, Muscle, and Kidney Related Diseases
10.3389/fcell.2024.1433857 · 2024 · External reference
Empagliflozin Activates Sestrin2‐Mediated AMPK/mTOR Pathway and Ameliorates Lipid Accumulation in Obesity‐Related Nonalcoholic Fatty Liver Disease
10.3389/fphar.2022.944886 · 2022 · External reference
The Effectiveness of Curcumin, Resveratrol, and Silymarin on MASLD: A Systematic Review and Meta‐Analysis
10.1002/fsn3.4595 · 2024 · External reference
Advanced Effect of Curcumin and Resveratrol on Mitigating Hepatic Steatosis in Metabolic Associated Fatty Liver Disease via the PI3K/AKT/mTOR and HIF‐1/VEGF Cascade
10.1016/j.biopha.2023.115279 · 2023 · External reference
Hepatic Steatosis as a Marker of Metabolic Dysfunction
10.3390/nu7064995 · 2015 · External reference
Fisetin as a Promising Agent in Non‐Alcoholic Fatty Liver Disease: Insights Into Pathogenic Mechanisms and Therapeutic Potential
2025 · External reference
Excess Triglycerides in Very Low‐Density Lipoprotein (VLDL) Estimated From VLDL‐Cholesterol Could Be a Useful Biomarker of Metabolic Dysfunction Associated Steatotic Liver Disease in Patients With Type 2 Diabetes
10.5551/jat.65164 · 2025 · External reference
New Insights Into the Role of Dietary Triglyceride Absorption in Obesity and Metabolic Diseases
10.3389/fphar.2023.1097835 · 2023 · External reference
Insulin Resistance and Adipose Tissue Interactions as the Cornerstone of Metabolic (Dysfunction)‐Associated Fatty Liver Disease Pathogenesis
10.3748/wjg.v29.i25.3999 · 2023 · External reference
Pathogenesis of MASLD and MASH–Role of Insulin Resistance and Lipotoxicity
10.1111/apt.17930 · 2024 · External reference
The Role of Macrophages in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
10.1038/s41575-018-0082-x · 2019 · External reference
Hepatic Macrophage as a Key Player in Fatty Liver Disease
10.3389/fimmu.2021.708978 · 2021 · External reference
Macrophage Polarization and Reprogramming in Acute Inflammation: A Redox Perspective
10.3390/antiox11071394 · 2022 · External reference
Empagliflozin Alleviates Hepatic Steatosis and Oxidative Stress via the NRF1 Pathway in High‐Fat Diet‐Induced Mouse Model of Metabolic Dysfunction‐Associated Steatotic Liver Disease
10.3390/ijms26094054 · 2025 · External reference
The Therapeutic Effects of Resveratrol on Hepatic Steatosis in High‐Fat Diet‐Induced Obese Mice by Improving Oxidative Stress, Inflammation and Lipid‐Related Gene Transcriptional Expression
10.1007/s00795-019-00216-7 · 2019 · External reference
Resveratrol Supplement Inhibited the NF‐κB Inflammation Pathway Through Activating AMPKα‐SIRT1 Pathway in Mice With Fatty Liver
10.1007/s11010-016-2807-x · 2016 · External reference
Induction of Adipose Tissue Browning as a Strategy to Combat Obesity
10.3390/ijms21176241 · 2020 · External reference
Can Resveratrol Modulate Sirtuins in Obesity and Related Diseases? A Systematic Review of Randomized Controlled Trials
10.1007/s00394-021-02623-y · 2021 · External reference
The Role of Hepatic SIRT1: From Metabolic Regulation to Immune Modulation and Multi‐Target Therapeutic Strategies
2025 · External reference
Involvement of SIRT1‐Mediated Aging in Liver Diseases
10.3389/fcell.2025.1548015 · 2025 · External reference
AMPK/SIRT1/PGC‐1α Signaling Pathway: Molecular Mechanisms and Targeted Strategies From Energy Homeostasis Regulation to Disease Therapy
10.1111/cns.70657 · 2025 · External reference
Recent Advances in Anti‐Inflammation via AMPK Activation
10.1016/j.heliyon.2024.e33670 · 2024 · External reference
SIRT1 Is Required for AMPK Activation and the Beneficial Effects of Resveratrol on Mitochondrial Function
10.1016/j.cmet.2012.04.003 · 2012 · External reference
